RxDoctor Payments Data

David Goldgrab, DO

Interventional Cardiology · Brandon, FLNPI 1144675331

Payments from drug & device makers

$4,135in general payments, 2019–2025

Across 61 payments — averaging $67.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Shockwave Medical, Inc$561
  • Boston Scientific$408
  • Cardiovascular Systems Inc.$234
  • Cardiva Medical, Inc.$228
  • Medtronic$149
  • plus $638 from 9 others

What the payments were for

  • Travel & lodging$92922%
  • Food & beverage$2,79368%
  • Education$41210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,135 in reported general payments places this provider in the 25th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$277,055
Medicare patients
1,084
Services billed
2,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$75,010
XareltoRivaroxaban12$12,803
BrilintaTicagrelor12$6,901
FarxigaDapagliflozin Propanediol12$6,055
Metoprolol Succinate92$1,039
Nifedipine ErNifedipine12$603
ClopidogrelClopidogrel Bisulfate51$393
Rosuvastatin Calcium34$393
Amiodarone Hcl19$285
Atorvastatin Calcium45$256
Losartan Potassium40$252
Amlodipine Besylate33$221
Lisinopril22$188
Carvedilol23$138
Furosemide29$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$75,01064 claims
AstraZenecaBrilinta, Farxiga$125$12,95624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →